GlassScriptPhysician profile
Gregory C Jesteadt
NPI 1083631170
$4,719.62
in general payments reported to CMS, 2019-2025
31 companies · $792 in 2025
The $792 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $198 · 2021: $953 · 2022: $677 · 2023: $867 · 2024: $1,026 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,671 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,671.23 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $784.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $582.42 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $505.52 | 2019-2025 | Jardiance |
| Pfizer INC. | $470.48 | 2019-2025 | |
| Abbvie INC. | $468.00 | 2021-2025 | |
| Lilly USA, LLC | $373.80 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $302.29 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $164.90 | 2019-2025 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $152.82 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $137.57 | 2022-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Amarin Pharma, INC. | $137.47 | 2019-2021 | |
| Glaxosmithkline, LLC. | $92.84 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $67.83 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.76 | 2021-2024 | Xifaxan, Trulance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $48.08 | 2022-2024 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $40.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $39.78 | 2023 | Keveyis |
| Janssen Pharmaceuticals, INC | $33.34 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $27.75 | 2024-2025 | Rexulti |
| Dexcom, INC. | $27.16 | 2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $17.83 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $17.68 | 2025 | Opsumit, Uptravi |
| Seqirus USA INC | $16.56 | 2022 | |
| Astellas Pharma US INC | $16.04 | 2020 | |
| Currax Pharmaceuticals LLC | $14.28 | 2023 | Onzetra Xsail, Contrave |
| Novartis Pharmaceuticals Corporation | $13.46 | 2019 | |
| Sanofi Pasteur INC. | $13.22 | 2020 | |
| Depuy Synthes Sales INC. | $13.08 | 2019 | |
| Boston Scientific Corporation | $12.69 | 2023 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Jesteadt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.